Literature DB >> 22226576

Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children.

Xiao-Jun Xu1, Yong-Min Tang, Hua Song, Shi-Long Yang, Wei-Qun Xu, Ning Zhao, Shu-Wen Shi, He-Ping Shen, Jun-Qing Mao, Ling-Yan Zhang, Bin-Hua Pan.   

Abstract

OBJECTIVE: The study goal was to determine the diagnostic accuracy of a specific cytokine pattern including interferon-gamma (IFN-γ), interleukin (IL)-10, and IL-6 for hemophagocytic lymphohistiocytosis (HLH) in febrile children. STUDY
DESIGN: In this prospective study, 756 patients with fever admitted to a hematology-oncology unit were enrolled. The causes of fever were documented and the serum cytokines, including IFN-γ, tumor necrosis factor-alpha (TNF-α), IL-10, IL-6, IL-4, and IL-2, were determined using cytometric bead array techniques.
RESULTS: Of 1474 episodes of fever that were analyzed, 71 episodes of HLH manifested a specific cytokine pattern of highly increased levels of IFN-γ (median level: 1088.5 pg/mL) and IL-10 (623.5 pg/mL) but a moderately increased level of IL-6 (51.1 pg/mL). IL-6 was predominantly increased to varied extents in patients in the sepsis group (244.6 pg/mL) and the nonsepsis infection group (34.7 pg/mL). The diagnostic accuracy of IFN-γ and IL-10 for HLH was 99.5% and 92.8%, respectively. By applying the cutoff point of 100 pg/mL, IFN-γ had a sensitivity of 94.4% and a specificity of 97.2% for HLH. When using the criteria of IFN-γ >75 pg/mL and IL-10 >60 pg/mL, the specificity reached 98.9% and the sensitivity was 93.0%.
CONCLUSIONS: The specific cytokine pattern of markedly elevated levels of IFN-γ and IL-10 with only modestly elevated IL-6 levels has high diagnostic accuracy for HLH and may be a useful approach to differentiate HLH from infection.
Copyright © 2012 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22226576     DOI: 10.1016/j.jpeds.2011.11.046

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  68 in total

1.  Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.

Authors:  Julie C Fitzgerald; Scott L Weiss; Shannon L Maude; David M Barrett; Simon F Lacey; J Joseph Melenhorst; Pamela Shaw; Robert A Berg; Carl H June; David L Porter; Noelle V Frey; Stephan A Grupp; David T Teachey
Journal:  Crit Care Med       Date:  2017-02       Impact factor: 7.598

2.  EBV-HLH children with reductions in CD4+ T cells and excessive activation of CD8+ T cells.

Authors:  Cheng Yang; Xiujuan Zhu; Ting Zhang; Qing Ye
Journal:  Pediatr Res       Date:  2017-08-16       Impact factor: 3.756

3.  Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections.

Authors:  Dana T Lounder; Qiong Bin; Cristina de Min; Michael B Jordan
Journal:  Blood Adv       Date:  2019-01-08

4.  Analysis of the molecular mechanism underlying bone marrow necrosis with acute lymphoblastic leukemia.

Authors:  Hiroshi Moritake; Megumi Obara; Naoki Sameshima; Yujiro Asada; Hiroyuki Komatsu; Nobuyuki Hyakuna; Kanji Sugita; Yasushi Ishida; Motohiro Kato; Akihiko Tanizawa; Takao Deguchi; Toshihiko Imamura; Akira Kitanaka; Kazuya Shimoda; Sachiyo Kamimura; Hiroyuki Nunoi
Journal:  Int J Hematol       Date:  2015-07-17       Impact factor: 2.490

Review 5.  CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.

Authors:  Shannon L Maude; David T Teachey; David L Porter; Stephan A Grupp
Journal:  Blood       Date:  2015-05-21       Impact factor: 22.113

6.  Lymphocyte-independent pathways underlie the pathogenesis of murine cytomegalovirus-associated secondary haemophagocytic lymphohistiocytosis.

Authors:  E Brisse; M Imbrechts; T Mitera; J Vandenhaute; N Berghmans; L Boon; C Wouters; R Snoeck; G Andrei; P Matthys
Journal:  Clin Exp Immunol       Date:  2018-01-18       Impact factor: 4.330

Review 7.  Hemophagocytic Syndrome and Critical Illness: New Insights into Diagnosis and Management.

Authors:  Zuzana Tothova; Nancy Berliner
Journal:  J Intensive Care Med       Date:  2014-01-08       Impact factor: 3.510

8.  A xenograft model of macrophage activation syndrome amenable to anti-CD33 and anti-IL-6R treatment.

Authors:  Mark Wunderlich; Courtney Stockman; Mahima Devarajan; Navin Ravishankar; Christina Sexton; Ashish R Kumar; Benjamin Mizukawa; James C Mulloy
Journal:  JCI Insight       Date:  2016-09-22

9.  Materials design at the interface of nanoparticles and innate immunity.

Authors:  Gregory Lee Szeto; Erin B Lavik
Journal:  J Mater Chem B       Date:  2016-01-29       Impact factor: 6.331

10.  Medical management of side effects related to CAR T cell therapy in hematologic malignancies.

Authors:  Manjusha Namuduri; Renier J Brentjens
Journal:  Expert Rev Hematol       Date:  2016-05-19       Impact factor: 2.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.